Nephros, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6406714005
USD
5.79
0.48 (8.95%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Nephros, Inc. stock-summary
stock-summary
Nephros, Inc.
Pharmaceuticals & Biotechnology
Nephros, Inc. (Nephros), is a commercial-stage company that develops and sells water purification products to medical devices and commercial markets. In medical device markets, its filters are generally classified as ultrafilters, and are used primarily by hospitals for the prevention of infection from water-borne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. In commercial markets, the Company manufactures and sell filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. Marketed under both the Nephros and AETHER brands. The Company’s product lines are: Water Filtration Products and Specialty Renal Products (HDF System). The Company’s subsidiary, Specialty Renal Products, Inc. (SRP), is a development-stage medical device company focused primarily on developing hemodiafiltration (HDF) technology.
Company Coordinates stock-summary
Company Details
380 Lackawanna Pl , SOUTH ORANGE NJ : 07079-1704
stock-summary
Tel: 1 201 3435202
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (2.96%)

Foreign Institutions

Held by 4 Foreign Institutions (0.41%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Andrew Astor
President, Chief Executive Officer, Director
Mr. Thomas Gwydir
Director
Ms. Alisa Lask
Director
Malcom Persen
Director
Mr. Oliver Spandow
Director
Mr. Arthur Amron
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
4 Million
(Quarterly Results - Jun 2025)
Net Profit:
0 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 42 Million (Micro Cap)

stock-summary
P/E

36.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.49

stock-summary
Return on Equity

13.82%

stock-summary
Price to Book

4.34